Results 241 to 250 of about 788,607 (367)

Factor Xa inhibitors: critical considerations for clinical development and testing. [PDF]

J Thromb Thrombolysis, 2021
Becker RC.
europepmc   +1 more source

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension. [PDF]

Ann Med
Kaksonen M, Simonen P, Lassila R, Pentikäinen M.   +3 more
europepmc   +1 more source

1P048 Flexible docking multicanonical molecular dynamics simulations between factor Xa and its inhibitors(1. Protein structure and dynamics (I),Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)

, 2006
Narutoshi Kamiya, Yasushige Yonezawa, Haruki Nakamura   +2 more
openalex   +2 more sources

Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly Lutzomyia longipalpis Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo [PDF]

, 2012
Nicolas Collin, Teresa C. F. Assumpção, Daniella M. Mizurini, Dana C. Gilmore, Angélica Dutra-Oliveira, Michail Kotsyfakis, Anderson Sá‐Nunes, Clarissa Teixeira, José M. C. Ribeiro, Robson Q. Monteiro, Jesús G. Valenzuela, Ivo M.B. Francischetti   +11 more
openalex   +1 more source

3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors. [PDF]

J Thromb Thrombolysis
Hays WB, Billups K, Nicholson J, Bailey AM, Gregory H, Weeda ER, Weant KA.   +6 more
europepmc   +1 more source

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors. [PDF]

J Atheroscler Thromb, 2022
Terakami T, Nagaya S, Hayashi K, Furusho H, Fujino N, Kato T, Asakura H, Morishita E.   +7 more
europepmc   +1 more source

A computational modeling and molecular dynamics study of the Michaelis complex of human protein Z-dependent protease inhibitor (ZPI) and factor Xa (FXa)

, 2009
V. Chandrasekaran, Chang Jun Lee, Ping Lin, Robert E. Duke, Lee G. Pedersen   +4 more
openalex   +4 more sources

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +1 more source

Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Cureus, 2021
Shrestha DB, Budhathoki P, Adhikari A, Shrestha S, Khati N, Mir WAY, Joshi T, Shrestha A.   +7 more
europepmc   +1 more source

Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors VI. A Series of New Derivatives Containing N,S- and N,SO2-Spiro Acetal Scaffolds

, 2007
Fumihiko Saitoh, Hidemitsu Nishida, Takafumi Mukaihira, Naoto Kosuga, Munetaka Ohkouchi, Tomokazu Matsusue, Ikuya Shiromizu, Yoshitaka Hosaka, Miwa Matsumoto, Ichiro Yamamoto   +9 more
openalex   +2 more sources